Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa⦠read more
Healthcare
Biotechnology
29 years
USD
Exclusive to Premium users
$2.88
Price-3.20%
-$0.09
$104.161m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$1.235m
-
1y CAGR-
3y CAGR-
5y CAGR-$426k
-
1y CAGR-
3y CAGR-
5y CAGR-$0.56
-
1y CAGR-
3y CAGR-
5y CAGR-$53.783m
$87.250m
Assets$141.033m
Liabilities$134.658m
Debt154.3%
10x
Debt to EBITDA-$36.275m
-
1y CAGR-
3y CAGR-
5y CAGR